TFF Pharmaceuticals, Inc. (TFFP)

NASDAQ: TFFP · IEX Real-Time Price · USD
5.76
-0.12 (-2.04%)
At close: Feb 26, 2024, 4:00 PM
5.28
-0.48 (-8.33%)
After-hours: Feb 27, 2024, 4:06 PM EST
-2.04%
Market Cap 13.62M
Revenue (ttm) 932,323
Net Income (ttm) -23.85M
Shares Out 2.37M
EPS (ttm) -13.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,553
Open 6.12
Previous Close 5.88
Day's Range 5.23 - 6.12
52-Week Range 4.55 - 23.00
Beta 1.26
Analysts Strong Buy
Price Target 137.50 (+2,287.15%)
Earnings Date Apr 1, 2024

About TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powde... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 15
Stock Exchange NASDAQ
Ticker Symbol TFFP
Full Company Profile

Financial Performance

In 2022, TFFP's revenue was $495,805, an increase of 462.39% compared to the previous year's $88,161. Losses were -$31.77 million, 2.36% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TFFP stock is "Strong Buy." The 12-month stock price forecast is $137.5, which is an increase of 2,287.15% from the latest price.

Price Target
$137.5
(2,287.15% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference

FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

4 weeks ago - GlobeNewsWire

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

Presentation will feature initial data from the Company's ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC), which is being developed to prevent lung transplant rejection Presentation wi...

7 weeks ago - GlobeNewsWire

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause morta...

2 months ago - GlobeNewsWire

TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET

2 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023 Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023

2 months ago - GlobeNewsWire

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

2 months ago - GlobeNewsWire

TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023

FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm ET to provide overv...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

Research shows the Company's Thin Film Freezing can reformulate broad range of monoclonal antibodies in combination with Aptar Pharma's Unidose (UDS) Powder Nasal Spray System for intranasal delivery ...

3 months ago - GlobeNewsWire

TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023

Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET

4 months ago - GlobeNewsWire

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

5 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...

5 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...

6 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

FORT WORTH, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inno...

6 months ago - GlobeNewsWire

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inno...

7 months ago - GlobeNewsWire

TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inno...

7 months ago - GlobeNewsWire

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock

FORT WORTH, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inno...

7 months ago - GlobeNewsWire

TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023

Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ET Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ET

7 months ago - GlobeNewsWire

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections

DUBLIN, Ireland and FORT WORTH, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Uniphar Durbin Ireland Limited (“Durbin” or the “Company”), a part of Uniphar Group's Product Access Division and a leading spe...

7 months ago - GlobeNewsWire

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered Unive...

8 months ago - GlobeNewsWire

TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug produ...

10 months ago - GlobeNewsWire

TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

FORT WORTH, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innov...

10 months ago - GlobeNewsWire

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innov...

10 months ago - GlobeNewsWire